ArticleFrontiers in cardiovascular medicine2025
Case Report: Pneumomediastinum and pulmonary embolism in a 19-year-old with focal segmental glomerulosclerosis: a rare double-complication of corticosteroid therapy.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Focal Segmental Glomerulosclerosis (FSGS) is a common aetiology of nephrotic syndrome and a leading cause of end-stage renal disease. Corticosteroid therapy is considered the first-line treatment in patients with proteinuria, but it carries a heterogeneous range of common and rare complications. Case summary: We report the case of a 19-year-old patient, recently diagnosed with FSGS secondary to anabolic steroid use and receiving glucocorticoid therapy, who presented to our emergency department with acute respiratory distress and neck swelling. He was subsequently diagnosed with pneumomediastinum and acute bilateral saddle pulmonary embolism (PE). Discussion: The rare occurrence of FSGS treated with glucocorticoid therapy, complicated by severe thromboembolic events and pneumomediastinum, emphasizes the complexity of managing the treatment of a young patient by balancing the risks and benefits and tailoring the dosage to achieve maximal therapeutic effect with minimal adverse events. Conclusion: Close monitoring should be provided to patients with a procoagulant status due to nephrotic syndrome, as well as to those at additional risk from corticosteroid treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.